Dabigatran

Source: Wikipedia, the free encyclopedia.

Dabigatran
Clinical data
Trade namesPradaxa, Pradax, Prazaxa, others
Other namesBIBR-953, BIBR-1048
AHFS/Drugs.comMonograph
MedlinePlusa610024
License data
Pregnancy
category
Routes of
administration
By mouth
Drug classDirect thrombin inhibitor
ATC code
Legal status
Legal status
JSmol)
  • CN1C=2C(=CC(C(N(CCC(O)=O)C3=CC=CC=N3)=O)=CC2)N=C1CNC4=CC=C(C(=N)N)C=C4

  • as etexilate: CN1C=2C(=CC(C(N(CCC(OCC)=O)C3=CC=CC=N3)=O)=CC2)N=C1CNC4=CC=C(C(NC(OCCCCCC)=O)=N)C=C4
  • InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
  • Key:YBSJFWOBGCMAKL-UHFFFAOYSA-N

  • as etexilate: InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
  • Key:KSGXQBZTULBEEQ-UHFFFAOYSA-N
 ☒NcheckY (what is this?)  (verify)

Dabigatran, sold under the brand name Pradaxa among others, is an

blood clots and to prevent stroke in people with atrial fibrillation.[6][7] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots.[6] It is used as an alternative to warfarin and does not require monitoring by blood tests.[6] In a meta analysis of 7 different studies, there was no benefit of dabigatran over warfarin in preventing ischemic stroke; however, dabigatran were associated with a lower hazard for intracranial bleeding compared with warfarin, but also had a higher risk of gastrointestinal bleeding relative to warfarin.[8] It is taken by mouth.[6]

Common side effects include bleeding and

bleeding around the spine and allergic reactions such as anaphylaxis.[6] In cases of severe bleeding, it can be reversed with the antidote, idarucizumab.[6] Use is not recommended during pregnancy or breastfeeding.[6] Compared to warfarin it has fewer interactions with other medications.[9] It is a direct thrombin inhibitor.[7]

Dabigatran was approved for medical use in the United States in 2010.

Medical uses

Dabigatran is used to prevent

low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.[4]

It appears to be as effective as warfarin in preventing non-hemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.[14][15][16]

In 2022, a comparative study was performed on direct oral anticoagulants for patients with atrial fibrillation. Results demonstrated apixaban use was associated with lower risk for gastrointestinal bleeding and similar rates of ischemic stroke or systemic embolism, intracerebral brain hemorrhage, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban.[17]

Contraindications

Dabigatran is contraindicated in patients who have active pathological bleeding, since dabigatran can increase bleeding risk and can also cause serious and potentially life-threatening bleeds.[4] Dabigatran is also contraindicated in patients who have a history of serious hypersensitivity reaction to dabigatran (e.g. anaphylaxis or anaphylactic shock).[4] The use of dabigatran should also be avoided in patients with mechanical prosthetic heart valves due to the increased risk of thromboembolic events (e.g. valve thrombosis, stroke, and myocardial infarction) and major bleeding associated with dabigatran in this population.[4][18][19]

Current FDA guidelines states that patients with mechanical heart valves should not be using dabigatran. The safety and efficacy of Pradaxa (dabigatran) were evaluated in the European RE-ALIGN trial in 2012. RE-ALIGN was terminated early because the Pradaxa treatment group had significantly more thromboembolic events and major bleeding than warfarin and determined to be contraindicated for use in patients with mechanical heart valves.[20] Further studies are needed in order to determine effects of dabigatran on patients with bioprosthetic valves.

Dabigatran is poorly excreted in breastmilk and does not appear to require any limitations to breastfeeding.[21] However, data is limited and further studies are needed.

Adverse effects

The most commonly reported side effect of dabigatran is gastrointestinal upset. When compared with people anticoagulated with warfarin, patients taking dabigatran had fewer life-threatening bleeds, fewer minor and major bleeds, including intracranial bleeds, but the rate of gastrointestinal bleeding was significantly higher. Dabigatran capsules contain tartaric acid, which lowers the gastric pH and is required for adequate absorption. The lower pH has previously been associated with

dyspepsia; some hypothesize that this plays a role in the increased risk of gastrointestinal bleeding.[22] If a small amount of GI bleeding is diagnosed, the clinicians may consider adding H2 receptor inhibitor (H2RA), proton pump inhibitors (PPIs) and mucosal protective agent. In severe bleeding, measures include discontinuation of dabigatran immediately, and administration of prothrombin complex concentrate, packed red blood cells, fresh frozen plasma, the use of specific reversal agents such as idarucizumab for dabigatran, and emergency endoscopic management.[23]

A small but significantly increased risk of myocardial infarctions (heart attacks) has been noted when combining the safety outcome data from multiple trials.[24]

Reduced doses should be used in those with poor kidney function.[25]

Dabigatran intake has also been reported to cause esophageal injury or esophagitis. In a 2016 study by Toya et al., roughly 20% of patients suffered esophageal mucosa damage.[26] It has been theorized that the tartaric-acid core in the drug adheres and damages the esophagus, and then the damaged esophageal mucosa exfoliates after peristalsis.[27] Additionally, patients with limited mobility, reduced salivary secretion, and low water consumption will increase the possibility of contact by dabigatran with the esophageal mucosa.[23]

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial showed that impairment of liver function caused by dabigatran occurred in the same frequency as warfarin[28]

Pharmacology

Mechanism of action

Dabigatran reversibly binds to the active site on the

coagulation factors. Furthermore, dabigatran can inactivate thrombin even when thrombin is fibrin-bound; it reduces thrombin-mediated inhibition of fibrinolysis and, therefore, may enhance fibrinolysis.[29]

Pharmacokinetics

Dabigatran has a half-life of approximately 12–14 h and exerts a maximum anticoagulation effect within 2–3 hours after ingestion.[

proton pump inhibitor.[30] Dabigatran excretion through P-glycoprotein pumps is slowed in patients taking strong p-glycoprotein pump inhibitors such as quinidine, verapamil, and amiodarone, thus raising plasma levels of dabigatran.[31]

Dabigatran is available as dabigatran etexilate mesilate, formulated as the prodrug dabigatran etexilate.[4][6][31]

History

Dabigatran (then compound BIBR-953) was discovered from a panel of chemicals with similar structure to

orally absorbed prodrug, BIBR 1048 (dabigatran etexilate).[32]

In March 2008, the

The National Health Service (NHS) in Britain authorized dabigatran for use in preventing blood clots in hip and knee replacement surgery patients. According to a BBC article in 2008, Dabigatran was expected to cost the NHS £4.20 per day, which was similar to several other anticoagulants.[34]

Initially, there was no specific way to reverse the anticoagulant effect of dabigatran in the event of a major bleeding event,[35] unlike for warfarin.[36] Since then, the dabigatran-specific antidote idarucizumab, a humanized monoclonal antibody for intravenous administration, was developed, and received Food and Drug Administration (FDA) approval in 2015.[37]

Pradaxa received a Notice of Compliance (NOC) from Health Canada in June 2008,[38] for the prevention of blood clots in patients who have undergone total hip or total knee replacement surgery. Approval for atrial fibrillation patients at risk of stroke came in October 2010.[39][40]

The U.S. Food and Drug Administration (FDA) approved Pradaxa in October 2010, for prevention of stroke in patients with non-valvular atrial fibrillation.[41][42][43][44] The approval came after an advisory committee recommended the drug for approval in September 2010,[45] although caution is still urged by some outside experts.[46]

In February 2011, the American College of Cardiology Foundation and the American Heart Association added dabigatran to their guidelines for management of non-valvular atrial fibrillation with a class I recommendation.[47]

In May 2014, the FDA reported the results of a large study comparing dabigatran with warfarin in 134,000 Medicare patients. The agency concluded that dabigatran is associated with a lower risk of overall mortality, ischemic stroke, and bleeding in the brain than warfarin. Gastrointestinal bleeding was more common in those treated with dabigatran than in those treated with warfarin. The risk of heart attack was similar between the two drugs. The FDA reiterated its opinion that dabigatran's overall risk/benefit ratio is favorable.[48]

In July 2014, a series of investigations accused the privately held Boehringer Ingelheim pharmaceutical group of withholding critical information about the need for monitoring to protect patients from severe bleeding, particularly in the elderly. Review of internal communications between Boehringer researchers and employees by the FDA and the EMA revealed that Boehringer researchers had found evidence that serum levels of dabigatran vary widely. The BMJ investigation suggested that Boehringer had a financial motive to withhold this concern from regulatory health agencies because the data conflicted with their extensive marketing of dabigatran as an anticoagulant that does not require monitoring.[49][50] In August 2012, Pradaxa claims filed in U.S. federal courts were consolidated into a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. In May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug was alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.[51]

References

  1. ^ "Dabigatran (Pradaxa) Use During Pregnancy". Drugs.com. 27 December 2018. Archived from the original on 1 October 2020. Retrieved 16 May 2020.
  2. ^ "Pradaxa Product information". health-products.canada.ca. 22 October 2009. Retrieved 13 November 2023.
  3. ^ "Summary of Product Characteristics (SmPC)". (emc). 15 September 2022. Archived from the original on 21 April 2023. Retrieved 13 November 2023.
  4. ^ a b c d e f g "Pradaxa- dabigatran etexilate mesylate capsule". DailyMed. 6 July 2020. Archived from the original on 28 June 2021. Retrieved 13 November 2020.
  5. ^ "Pradaxa EPAR". European Medicines Agency. 22 March 2023. Archived from the original on 5 June 2023. Retrieved 13 November 2023.
  6. ^ a b c d e f g h i j k l m "Dabigatran Etexilate Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 27 March 2019.
  7. ^ .
  8. .
  9. .
  10. . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. ^ "Dabigatran - Drug Usage Statistics". ClinCalc. Archived from the original on 13 November 2022. Retrieved 7 October 2022.
  12. ^ "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Archived from the original on 12 February 2021. Retrieved 12 February 2021.
  13. ^ "Dabigatran Etexilate Accord". European Medicines Agency. 31 May 2023. Retrieved 2 June 2023.
  14. PMID 24455237
    .
  15. .
  16. PMID 30480925. Report No.: 18-EHC018-EFReport No.: 2018-SR-04. Archived
    from the original on 29 March 2019. Retrieved 31 May 2023.
  17. .
  18. ^ "FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves". U.S. Food and Drug Administration (FDA). Archived from the original on 2 November 2014. Retrieved 29 October 2014.
  19. PMID 23991661
    .
  20. ^ "FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 21 June 2019. Archived from the original on 27 February 2023. Retrieved 27 February 2023.
  21. from the original on 2 May 2023, retrieved 27 February 2023
  22. .
  23. ^ .
  24. .
  25. ^ "18/12/2014 Pradaxa -EMEA/H/C/000829 -II/0073".[permanent dead link]
  26. S2CID 2601542
    .
  27. .
  28. .
  29. .
  30. .
  31. ^ a b "Pradaxa Summary of Product Characteristics" (2018) Archived 5 July 2019 at the Wayback Machine. European Medicines Agency.
  32. PMID 11960487
    .
  33. ^ "Pradaxa EPAR". European Medicines Agency. Archived from the original on 2 August 2012. Retrieved 30 January 2011.
  34. ^ "Clot drug 'could save thousands'". BBC News Online. 20 April 2008. Archived from the original on 15 January 2009. Retrieved 21 April 2008.
  35. S2CID 37404563
    . Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity.
  36. .
  37. .
  38. ^ "Summary Basis of Decision (SBD): Pradax" Archived 14 July 2016 at the Wayback Machine Health Canada. 6 November 2008.
  39. ^ Kirkey S (29 October 2010). "Approval of new drug heralds 'momentous' advance in stroke prevention". Montreal Gazette. Archived from the original on 16 June 2011. Retrieved 29 October 2010.
  40. ^ "Pradax (Dabigatran Etexilate) Gains Approval In Canada For Stroke Prevention In Atrial Fibrillation" Archived 24 April 2011 at the Wayback Machine Medical News Today. 28 October 2010.
  41. S2CID 7425216
    .
  42. .
  43. ^ "Boehringer wins first US OK in blood-thinner race". Reuters. 19 October 2010. Archived from the original on 4 May 2016. Retrieved 20 October 2010.
  44. ^ "FDA approves Pradaxa to prevent stroke in people with atrial fibrillation" (Press release). U.S. Food and Drug Administration (FDA). 19 October 2010. Archived from the original on 20 October 2010.
  45. ^ Shirley S. Wang (20 September 2010). "New Blood-Thinner Recommended by FDA Panel". The Wall Street Journal. Archived from the original on 24 April 2016. Retrieved 20 October 2010.
  46. S2CID 44917732
    .
  47. .
  48. ^ "FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin". U.S. Food and Drug Administration (FDA). 21 June 2019. Archived from the original on 11 November 2020. Retrieved 13 November 2020.
  49. PMID 25055829
    .
  50. .
  51. ^ Thomas K (28 May 2014). "$650 Million to Settle Blood Thinner Lawsuits". The New York Times. Archived from the original on 11 June 2021. Retrieved 26 November 2020.